Skip to main content

Adaptimmune to acquire Boston-area cell therapy company TCR² Therapeutics

The union will extend the cash runway of Adaptimmune into 2026.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.